JCS/JSCVS/JATS/JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure

Q: What is the clinical evidence from this study?

Study design: Review. Population: Advanced Heart Failure. Intervention: Implantable Left Ventricular Assist Device (LVAD).

doi:10.1253/circj.cj-21-0880

April 4, 2022Circulation JournalOpen Access

JCS/JSCVS/JATS/JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure

View Full Paper

Ask AI

Bookmark

Share

Structured PICO

P

Population

Patients with advanced heart failure requiring implantable left ventricular assist device (LVAD) therapy in Japan.

I

Intervention

Implantable Left Ventricular Assist Device (LVAD)

Limitations

Lack of randomized, prospective, multicenter, large-scale clinical trials for implantable LVAD therapy
Most knowledge in Japan is based on registries and small single-center studies rather than evidence-based medicine
No experience with destination therapy (DT) in Japan at the time of writing

Implication

This 2021 Japanese joint society guideline standardizes the indications and management of implantable LVADs for advanced heart failure, notably introducing destination therapy to clinical practice in Japan.

Abstract

aortic insufficiency ARB angiotensin II receptor blocker

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2022 study conducted a review in Advanced Heart Failure. Implantable Left Ventricular Assist Device (LVAD) was evaluated. The JCS/JSCVS/JATS/JSVS 2021 guidelines provide comprehensive recommendations for the indications, perioperative management, and long-term care of patients receiving implantable LVADs in Japan.

synapsesocial.com/papers/6a93fd548a8748f227d6949a https://doi.org/10.1253/circj.cj-21-0880